Author

Xizi Sun

Observed names: X. G. Sun, X. Sun

Institution: Relay Therapeutics (United States)

Observed institutions: The University of Texas MD Anderson Cancer Center, Duke University, The Lundquist Institute, Texas A&M University – Kingsville, Relay Therapeutics (United States), Durham VA Medical Center, Vanderbilt University Medical Center

OpenAlex ID: A5013203217

Metformin Use and Risk of Prostate Cancer: Results from the REDUCE Study

2015 · Tom Feng, Xizi Sun, et al. · Cancer Prevention Research · 37

Abstract PR008: MYTHIC: First-in-human (FIH) biomarker-driven phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1 amplification or deleterious alterations in FBXW7 or PPP2R1A

2023 · Timothy A Yap, Alison Schram, et al. · Molecular Cancer Therapeutics · 26

Efficacy of iron-supplement bars to reduce anemia in urban Indian women: a cluster-randomized controlled trial ,

2017 · Rajvi Mehta, Alyssa C Platt, et al. · American Journal of Clinical Nutrition · 20

Abstract CT262: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656)

2025 · Alison M. Schram, Elizabeth K. Lee, et al. · Cancer Research · 11

Phase II study of vlnorelbine in patients with hormone refractory prostate cancer

1997 · A. Caty, S. Oudard, et al. · European Journal of Cancer · 6

Characterization of a “low‐risk” cohort of grade group 2 prostate cancer patients: Results from the Shared Equal Access Regional Cancer Hospital database

2017 · Kathleen F McGinley, Xizi Sun, et al. · International Journal of Urology · 4

Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database

2015 · Kathleen F McGinley, Xizi Sun, et al. · International Journal of Urology · 2

Changes in cardiopulmonary reserves associated with neoadjuvant therapy in patients with esophageal cancer

2009 · W. L. Hofstetter, C. E. Hightower, et al. · Journal of Clinical Oncology · 2

Baseline subject characteristics to predict compliance with study-mandated prostate biopsy in men at risk of prostate cancer: Results from REDUCE.

2016 · Sean Fischer, Xizi Sun, et al. · Journal of Clinical Oncology · 1

Can Gleason 7 prostate cancer ever be low-risk? Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.

2015 · Kathleen F. McGinley, Xizi Sun, et al. · Journal of Clinical Oncology · 1

57 (PB045): Individualised schedule optimisation improves rates and severity of anaemia in patients (pts) treated with lunresertib (lunre), a PKMYT1 inhibitor, and camonsertib (cam), an ATR inhibitor, in the phase I MYTHIC study (NCT0485565)

2024 · M. Hojgaard, T.A. Yap, et al. · European Journal of Cancer

Pd40-12 Do Sicker People Have Worse Prostate Cancer-specific Outcomes After Radical Prostatectomy? Results From Search

2017 · Anna Teeter, Xizi Sun, et al. · The Journal of Urology

Mp04-01 Metformin Use and Risk of Prostate Cancer: Results From the Reduce Study

2016 · Tom Feng, Xizi Sun, et al. · The Journal of Urology

Pd34-07 Can Gleason 7 Prostate Cancer Ever Be Low-risk? Results From the Shared Equal Access Regional Cancer Hospital (search) Database

2015 · Kathleen McGinley, Xizi Sun, et al. · The Journal of Urology

Utilization and impact of surgical technique on the performance of pelvic lymph node dissection at radical prostatectomy: Results from the SEARCH database.

2015 · Kathleen F. McGinley, Xizi Sun, et al. · Journal of Clinical Oncology

Works count: 15

Citation count: 110

H-index: 5

I10-index: 4